Welcome! Click course links to visit the site sponsoring the free CME courses for Physicians. All courses are FREE & approved for AMA Pra CAT 1 credit required for Physician license renewal in most states. Posts are current and include expiration dates if applicable.

Update on New Treatments for NIDDM

Update on Emerging Novel Agents for the Treatment of Type 2 Diabetes:Focus on SGLT2 Inhibitors- Type 2 diabetes has reached an epidemic level in the United States. Management of the condition remains a major clinical challenge with only half of patients achieving their recommended glycemic goals. An emerging new class of agents to reduce hyperglycemia, sodium-glucose transporter 2 (SGLT2) inhibitors, offers the potential to improve glycemic control for many patients with type 2 diabetes through a novel mechanism of action. SGLT2 inhibitors reduce hyperglycemia by blocking renal glucose reabsorption. The goal of this continuing medical education activity is to prepare endocrinologists and primary care clinicians to appropriately incorporate SGLT2 inhibitors into type 2 diabetes treatment regimens when available, ultimately helping patients achieve better glycemic control.
Compare the mechanism of action of sodium-glucose cotransporter-2 (SGLT2) inhibitors with other agents used in type 2 diabetes.
Review the most current data on the safety, efficacy, and tolerability of SGLT2 inhibitors when used as monotherapy or in combination regimens for treatment of type 2 diabetes.
Describe the effects of SGLT2 inhibitors on other cardiovascular risk factors such as blood pressure, lipid profile, and body weight/waist circumference.
Summarize ongoing clinical trials of SGLT2 inhibitors in patients with type 2 diabetes.
1.0 Free AMA Pra CAT 1 CME for Physicians
Expires 2/7/14
This activity is supported by an independent educational grant from Boehringer Ingelheim Pharmaceuticals, Inc., which was made possible, in part, through collaboration with Eli Lilly and Company.